Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study

European Neuropsychopharmacology

Volumn 18, Issue 2, 2008, Pages 117-121

  Krivoy, Amir ^a   Weizman, Abraham ^a,b   Laor, Lucian ^a   Hellinger, Nurit ^a   Zemishlany, Zvi ^a,b   Fischel, Tsvi ^a,b  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Glutamate; Memantine; Negative signs; NMDA; Schizophrenia

Indexed keywords

CLOZAPINE; FLUPHENAZINE DECANOATE; GLUTAMIC ACID; MEMANTINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLOCK DRAWING TEST; COGNITIVE DEFECT; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; ISRAEL; MALE; NEUROBEHAVIORAL COGNITIVE EXAMINATION; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SCHIZOPHRENIA; SYMPTOM;

ADULT; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; FEMALE; HUMANS; INPATIENTS; MALE; MEMANTINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 37349021411     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.07.008     Document Type: Article

References (35)

1. Carpenter S.S., Hatchett A.D., and Fuller M.A. Catatonic schizophrenia and the use of memantine. Ann. Pharmacother. 40 2 (2006) 344-346
2. Danysz W., and Parsons C.G. Glycine and N-methyl-d-aspartate receptors physiological significance and possible therapeutic applications. Pharmacol. Rev. 50 (1998) 597-664
3. Danysz W., Parsons C.G., Mobius H.J., Stoffler E., and Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease: a unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res. 2 (2000) 85-87
4. Deutsch S.I., Rosse R.B., Schwratz B.L., and Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. 24 (2001) 43-49
5. Farber N.B. The NMDA receptor hypofunction model of psychosis. Ann. N.Y. Acad. Sci. 1003 (2003) 119-130
6. Gama C.S., Antunes P., Moser C., and Belmonte-de-Abreu P.S. Memantine as an adjunctive therapy for schizophrenia negative symptoms. Rev. Bras. Psiquiatr. 27 (2005) 257-258
7. In: Guy W. (Ed). Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology (revised) (1976), National Institute of Mental Health, Rockville, MD 217-221
8. Heim C., and Sontag K.H. Memantine prevents progressive functional neurodegeneration in rats. J. Neural Transm., Suppl. 46 (1995) 117-130
9. Ikonomidou C., and Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol. 1 (2002) 383-386
10. Jensen J.E., Miller J., Williamson P.C., et al. Focal changes in brain energy and phospholipids metabolism in first-episode schizophrenia: 31 31P-MRS P-chemical shift imaging study at 4 Tesla. Br. J. Psychiatry 184 (2004) 409-415
11. Kay S.R., Opler L.A., and Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 23 (1987) 99-110
12. Kiernan R.J., Mueller J., Langston J.W., and Van Dyke C. The Neurobehavioral Cognitive Status Examination: a brief but quantitative approach to cognitive assessment. Ann. Intern. Med. 107 4 (1987) 481-485
13. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers Jr. M.B., Charney D.S., Karper L.P., and Seibyl J.P. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51 (1994) 199-214
14. Lipton S.A., and Rosenberg P.A. Excitatory amino acids as a common pathway for neurologic disorders. N. Engl. J. Med. 330 (1994) 613-622
15. Lukoyanov N.V., and Paula-Barbosa M.M. Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol. Neurosci. Lett. 309 (2001) 45-48
16. Maldonado C., Cauli O., Rodriguez-Arias M., Aguilar M.A., and Minarro J. Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal. Behav. Brain Res. 144 (2003) 25-35
17. Millan M.J. N-methyl-d-Aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179 (2005) 30-53
18. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52 (1995) 998-1007
19. Orgogozo J.M., Rigaud A.S., Stoffller A., Mobius H.J., and Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia. Stroke 33 (2002) 1834-1839
20. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10 (1962) 799-812
21. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated NMDA receptor antagonist - a review of preclinical data. Neuropharmacology 38 (1999) 735-767
22. Peeters M., Maloteaux J.M., and Hermans E. Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci. Lett. 343 (2003) 205-209
23. Rands G.S. Memantine as a neuroprotective treatment in schizophrenia. Br. J. Psychiatry 186 (2005) 77-78
24. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348 (2003) 1333-1341
25. Rogawski M.A., and Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 3 (2003) 275-308
26. Silver H., Goodman C., Isakov V., Knoll G., and Modai I. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int. Clin. Psychopharmacol. 20 (2005) 319-326
27. Simpson G.M., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., Suppl. 212 (1970) 11-19
28. Sunderland T., Hill J.L., Mellow A.M., Lawlor B.A., Gundersheimer J., Newhouse P.A., et al. Clock drawing in Alzheimer's disease: a novel measure of dementia severity. J. Am. Geriatr. Soc. 37 8 (1989) 725-729
29. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324
30. Thomas C. Memantine and catatonic schizophrenia. Am. J. Psychiatry 162 (2005) 626
31. Tsapakis E.M., and Travis M.J. Glutamate and psychiatric disorders. Adv. Psychiatr. Treat. 8 (2002) 189-197
32. Valevski A., Modai I., Zbarski E., Zemishlany Z., and Weizman A. Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients. Clin. Neuropharmacol. 21 (1998) 355-357
33. Wilcock G.K. Memantine for treatment of dementia. Lancet Neurol. 2 (2003) 503-506
34. Yamada K., Kanba S., Ohnishi K., Ashikari I., Yagi G., and Asai M. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia. Biol. Psychiatry 41 10 (1997) 1062-1064
35. Zajaczkowski W., Quack G., and Danysz W. Infusion of MK-801 and memantine: contrasting effect on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol. 296 (1996) 239-246